NAPOLEON BT Study

A multicenter observational retrospective study of gemcitabine-plus alpha combination chemotherapy in patients with unresectable or recurrent biliary tract cancer (NAPOLEON BT Study) - NAPOLEON-BTS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053078

Enrollment

500

Registered

2023-12-12

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable or recurrent biliary tract cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 1. whose biliary tract cancer were diagnosed unresectable clinically and received gemcitabine-containing regimen from 01/01/2017 to 31/03/2024. 2. whose cancer were judged by abdominal CT or MRI. 3. whose pathological diagnosis before chemotherapy was not necessary. 4. of greater than or equal to 20 years old.

Exclusion criteria

Exclusion criteria: Patients 1. with active double cancers. 2. whom the doctor in-chief judged not to be indicated for this study.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Response rate, disease control rate, progression-free survival, and predictive or prognostic factors	—

Countries

Japan

Contacts

Public ContactToyodome Koshiro

Kagoshima University Graduate School of Medical and Dental Scie Digestive and Lifestyle Diseases

koshirotoyodome@gmail.com099-275-5326

Outcome results